Objectives The purpose of this study was to investigate the preventive effect of Sparassis crispa on type I diabetes.
Methods The preventive effect of S. crispa extract (0.6 g/kg/day) was investigated using a rat model of type I diabetes established by streptozotocin after 3-week oral administration. The diabetes-related factor index was examined using the ELISA test.
Results Compared to the model group, the S. crispa extract administration group showed lower diabetic weight lost (p < 0.01), lower fasting glucose levels and lower postprandial 2-hour blood glucose levels (p < 0.001). S. crispa extract administration can significantly alleviate STZ-induced decrease in glucose tolerance and reduce STZ-induced elevation in endotoxin and iNOS levels. It also effectively suppresses glycosylated hemoglobin accumulation and reduces total bile acid level.
Conclusions S. crispa extract has a good preventive effect on type I diabetes. This study provides a theoretical basis for its use in healthcare products and drugs for type I diabetes.